{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:55:03Z","timestamp":1788886503920,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T00:00:00Z","timestamp":1691539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019223","name":"Ministry of Health\u2014Kingdom of Saudi Arabia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019223","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13555-023-00991-3","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:01:32Z","timestamp":1691604092000},"page":"2129-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)"],"prefix":"10.1007","volume":"13","author":[{"given":"Mohammad Ibrahim Ahmad","family":"Fatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alkhalifah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaal Farhan Salman","family":"Alruwaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen Hamed Salem","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru\u2019aa","family":"Alharithy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr Mohammad","family":"Khardaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer Yousef","family":"Almudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Jedai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0573-6143","authenticated-orcid":false,"given":"Maysa Tariq Yousef","family":"Eshmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,9]]},"reference":[{"issue":"4","key":"991_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1067\/mjd.2000.103909","volume":"42","author":"S Madani","year":"2000","unstructured":"Madani S, Shapiro J. Alopecia areata update. J Am Acad Dermatol. 2000;42(4):549\u201366 (quiz 567\u201370).","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"991_CR2","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000092287","volume":"212","author":"M Kurosawa","year":"2006","unstructured":"Kurosawa M, et al. A comparison of the efficacy, relapse rate and side effects among three modalities of systemic corticosteroid therapy for alopecia areata. Dermatology. 2006;212(4):361\u20135.","journal-title":"Dermatology"},{"issue":"1","key":"991_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1346-8138.16207","volume":"49","author":"M Fukuyama","year":"2022","unstructured":"Fukuyama M, Ito T, Ohyama M. Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49(1):19\u201336.","journal-title":"J Dermatol"},{"issue":"5","key":"991_CR4","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/sj.jid.5701183","volume":"128","author":"T Ito","year":"2008","unstructured":"Ito T, et al. Maintenance of hair follicle immune privilege is linked to prevention of NK cell attack. J Investig Dermatol. 2008;128(5):1196\u2013206.","journal-title":"J Investig Dermatol"},{"issue":"2","key":"991_CR5","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0002-9440(10)63151-3","volume":"164","author":"T Ito","year":"2004","unstructured":"Ito T, et al. Collapse and restoration of MHC class-I-dependent immune privilege: exploiting the human hair follicle as a model. Am J Pathol. 2004;164(2):623\u201334.","journal-title":"Am J Pathol"},{"issue":"9","key":"991_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"L Xing","year":"2014","unstructured":"Xing L, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043\u20139.","journal-title":"Nat Med"},{"issue":"1","key":"991_CR7","first-page":"42","volume":"15","author":"K Jahn-Bassler","year":"2017","unstructured":"Jahn-Bassler K, et al. Sequential high- and low-dose systemic corticosteroid therapy for severe childhood alopecia areata. J Dtsch Dermatol Ges. 2017;15(1):42\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"1","key":"991_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40257-019-00479-x","volume":"21","author":"M Starace","year":"2020","unstructured":"Starace M, et al. Female androgenetic alopecia: an update on diagnosis and management. Am J Clin Dermatol. 2020;21(1):69\u201384.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"991_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1111\/j.1365-4362.1996.tb01610.x","volume":"35","author":"VK Sharma","year":"1996","unstructured":"Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol. 1996;35(1):22\u20137.","journal-title":"Int J Dermatol"},{"key":"991_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7194270","volume":"2020","author":"AA Alshahrani","year":"2020","unstructured":"Alshahrani AA, et al. Prevalence and clinical characteristics of alopecia areata at a tertiary care center in Saudi Arabia. Dermatol Res Pract. 2020;2020: 7194270.","journal-title":"Dermatol Res Pract"},{"issue":"9","key":"991_CR11","volume":"12","author":"A Al-Ajlan","year":"2020","unstructured":"Al-Ajlan A, et al. Prevalence of alopecia areata in Saudi Arabia: cross-sectional descriptive study. Cureus. 2020;12(9): e10347.","journal-title":"Cureus"},{"issue":"2","key":"991_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, et al. Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol. 2019;60(2):163\u201370.","journal-title":"Australas J Dermatol"},{"issue":"Suppl 1","key":"991_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.abd.2020.05.006","volume":"95","author":"PM Ramos","year":"2020","unstructured":"Ramos PM, et al. Consensus on the treatment of alopecia areata\u2014Brazilian Society of Dermatology. An Bras Dermatol. 2020;95(Suppl 1):39\u201352.","journal-title":"An Bras Dermatol"},{"key":"991_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.23736\/S0392-0488.19.06458-7","volume":"154","author":"A Rossi","year":"2019","unstructured":"Rossi A, et al. Italian guidelines in diagnosis and treatment of alopecia areata. G Ital Dermatol Venereol. 2019;154:609\u201323.","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"991_CR15","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/j.jaad.2020.09.028","volume":"84","author":"N Meah","year":"2021","unstructured":"Meah N, et al. The Alopecia Areata Consensus of Experts (ACE) study part II: results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata. J Am Acad Dermatol. 2021;84(6):1594\u2013601.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"991_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","volume":"83","author":"N Meah","year":"2020","unstructured":"Meah N, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. 2020;83(1):123\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"991_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jaad.2017.10.048","volume":"79","author":"EA Olsen","year":"2018","unstructured":"Olsen EA, et al. Objective outcome measures: collecting meaningful data on alopecia areata. J Am Acad Dermatol. 2018;79(3):470-478.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"991_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jaad.2021.08.043","volume":"86","author":"BA King","year":"2022","unstructured":"King BA, et al. Development of the alopecia areata scale for clinical use: results of an academic-industry collaborative effort. J Am Acad Dermatol. 2022;86(2):359\u201364.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"991_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40257-020-00545-9","volume":"21","author":"KW Wyrwich","year":"2020","unstructured":"Wyrwich KW, et al. Development of clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures for eyebrow, eyelash and nail assessment in alopecia areata. Am J Clin Dermatol. 2020;21(5):725\u201332.","journal-title":"Am J Clin Dermatol"},{"issue":"2 Pt 1","key":"991_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0190-9622(99)70195-7","volume":"40","author":"E Olsen","year":"1999","unstructured":"Olsen E, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol. 1999;40(2 Pt 1):242\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"991_CR21","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"EA Olsen","year":"2004","unstructured":"Olsen EA, et al. Alopecia areata investigational assessment guidelines\u2014Part II. National Alopecia Areata Foundation. J Am Acad Dermatol. 2004;51(3):440\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"991_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1046\/j.1365-4362.2003.01340.x","volume":"42","author":"S Ruiz-Doblado","year":"2003","unstructured":"Ruiz-Doblado S, Carrizosa A, Garc\u00eda-Hern\u00e1ndez MJ. Alopecia areata: psychiatric comorbidity and adjustment to illness. Int J Dermatol. 2003;42(6):434\u20137.","journal-title":"Int J Dermatol"},{"issue":"12","key":"991_CR23","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/j.1365-4362.1994.tb01018.x","volume":"33","author":"JY Koo","year":"1994","unstructured":"Koo JY, et al. Alopecia areata and increased prevalence of psychiatric disorders. Int J Dermatol. 1994;33(12):849\u201350.","journal-title":"Int J Dermatol"},{"issue":"11","key":"991_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1111\/j.1365-4632.2008.03743.x","volume":"47","author":"A Ghanizadeh","year":"2008","unstructured":"Ghanizadeh A. Comorbidity of psychiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. Int J Dermatol. 2008;47(11):1118\u201320.","journal-title":"Int J Dermatol"},{"issue":"6","key":"991_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000254503","volume":"131","author":"T Ikeda","year":"1965","unstructured":"Ikeda T. A new classification of alopecia areata. Dermatologica. 1965;131(6):421\u201345.","journal-title":"Dermatologica"},{"issue":"2 Pt 1","key":"991_CR26","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/0190-9622(91)70032-W","volume":"24","author":"PH van der Steen","year":"1991","unstructured":"van der Steen PH, et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol. 1991;24(2 Pt 1):227\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"2 Pt 1","key":"991_CR27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/0190-9622(91)70194-7","volume":"25","author":"A Tosti","year":"1991","unstructured":"Tosti A, et al. Trachyonychia associated with alopecia areata: a clinical and pathologic study. J Am Acad Dermatol. 1991;25(2 Pt 1):266\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"5951","key":"991_CR28","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1136\/bmj.1.5951.191","volume":"1","author":"A Du Vivier","year":"1975","unstructured":"Du Vivier A, Munro DD. Alopecia areata, autoimmunity, and Down\u2019s syndrome. Br Med J. 1975;1(5951):191\u20132.","journal-title":"Br Med J"},{"issue":"7302","key":"991_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature09114","volume":"466","author":"L Petukhova","year":"2010","unstructured":"Petukhova L, et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113\u20137.","journal-title":"Nature"},{"key":"991_CR30","doi-asserted-by":"publisher","first-page":"5966","DOI":"10.1038\/ncomms6966","volume":"6","author":"RC Betz","year":"2015","unstructured":"Betz RC, et al. Genome-wide meta-analysis in alopecia areata resolves HLA associations and reveals two new susceptibility loci. Nat Commun. 2015;6:5966.","journal-title":"Nat Commun"},{"issue":"18","key":"991_CR31","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687\u201399.","journal-title":"N Engl J Med"},{"issue":"4","key":"991_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"991_CR33","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000249714","volume":"168","author":"WW van der Schaar","year":"1984","unstructured":"van der Schaar WW, Sillevis Smith JH. An evaluation of PUVA-therapy for alopecia areata. Dermatologica. 1984;168(5):250\u20132.","journal-title":"Dermatologica"},{"issue":"6","key":"991_CR34","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/ijd.13572","volume":"56","author":"ME Herz-Ruelas","year":"2017","unstructured":"Herz-Ruelas ME, et al. Escalating dosimetry of UVA-1 in the treatment of alopecia areata. Int J Dermatol. 2017;56(6):653\u20139.","journal-title":"Int J Dermatol"},{"issue":"4","key":"991_CR35","doi-asserted-by":"publisher","first-page":"326","DOI":"10.4103\/0019-5154.113954","volume":"58","author":"A Ohtsuki","year":"2013","unstructured":"Ohtsuki A, et al. 308-nm excimer lamp for the treatment of alopecia areata: clinical trial on 16 cases. Indian J Dermatol. 2013;58(4):326.","journal-title":"Indian J Dermatol"},{"issue":"2","key":"991_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/14764172.2016.1248440","volume":"19","author":"S Mlacker","year":"2017","unstructured":"Mlacker S, et al. A review on laser and light-based therapies for alopecia areata. J Cosmet Laser Ther. 2017;19(2):93\u20139.","journal-title":"J Cosmet Laser Ther"},{"issue":"1","key":"991_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"991_CR38","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/ced.12776","volume":"41","author":"RC Lamb","year":"2016","unstructured":"Lamb RC, Young D, Holmes S. Retrospective review of diphencyprone in the treatment of alopecia areata. Clin Exp Dermatol. 2016;41(4):352\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"991_CR39","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjd.14040","volume":"173","author":"RA Kuin","year":"2015","unstructured":"Kuin RA, et al. Diphenylcyclopropenone in patients with alopecia areata. A critically appraised topic. Br J Dermatol. 2015;173(4):896\u2013909.","journal-title":"Br J Dermatol"},{"issue":"9","key":"991_CR40","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1346-8138.1999.tb02049.x","volume":"26","author":"VK Sharma","year":"1999","unstructured":"Sharma VK, Gupta S. Twice weekly 5 mg dexamethasone oral pulse in the treatment of extensive alopecia areata. J Dermatol. 1999;26(9):562\u20135.","journal-title":"J Dermatol"},{"issue":"8","key":"991_CR41","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/j.1365-4632.2008.03700.x","volume":"47","author":"T Rashidi","year":"2008","unstructured":"Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47(8):850\u20132.","journal-title":"Int J Dermatol"},{"issue":"2","key":"991_CR42","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaad.2009.10.031","volume":"62","author":"A Alkhalifah","year":"2010","unstructured":"Alkhalifah A, et al. Alopecia areata update: part II. Treatment. J Am Acad Dermatol. 2010;62(2):191\u2013202.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"991_CR43","doi-asserted-by":"publisher","first-page":"611","DOI":"10.4103\/0378-6323.45103","volume":"74","author":"S Aghaei","year":"2008","unstructured":"Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2008;74(6):611\u20133.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"991_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1067\/mjd.2002.119671","volume":"46","author":"CN Ellis","year":"2002","unstructured":"Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002;46(4):541\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl 2","key":"991_CR45","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"OShea, J.J.,","year":"2013","unstructured":"OShea, J.J., et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(Suppl 2):ii111\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"10387","key":"991_CR46","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329.","journal-title":"Lancet"},{"issue":"1","key":"991_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, et al. Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol. 2017;76(1):22\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"991_CR48","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1038\/jid.2014.260","volume":"134","author":"BG Craiglow","year":"2014","unstructured":"Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Investig Dermatol. 2014;134(12):2988\u201390.","journal-title":"J Investig Dermatol"},{"issue":"4","key":"991_CR49","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1001\/jamadermatol.2015.3772","volume":"152","author":"A Dhayalan","year":"2016","unstructured":"Dhayalan A, King BA. Tofacitinib citrate for the treatment of nail dystrophy associated with alopecia universalis. JAMA Dermatol. 2016;152(4):492\u20133.","journal-title":"JAMA Dermatol"},{"issue":"15","key":"991_CR50","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"J Mackay-Wiggan","year":"2016","unstructured":"Mackay-Wiggan J, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15): e89790.","journal-title":"JCI Insight"},{"issue":"6","key":"991_CR51","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495\u2013507.","journal-title":"N Engl J Med"},{"key":"991_CR52","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders; 2023. https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic [cited 20 February 2023]."},{"issue":"5","key":"991_CR53","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jdv.15489","volume":"33","author":"K Phan","year":"2019","unstructured":"Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019;33(5):850\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"991_CR54","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jaad.2018.06.064","volume":"80","author":"K Phan","year":"2019","unstructured":"Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(1):120-127.e2.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"991_CR55","doi-asserted-by":"publisher","first-page":"172","DOI":"10.5021\/ad.2008.20.4.172","volume":"20","author":"D Lee","year":"2008","unstructured":"Lee D, et al. Treatment of severe alopecia areata: combination therapy using systemic cyclosporine A with low dose corticosteroids. Ann Dermatol. 2008;20(4):172\u20138.","journal-title":"Ann Dermatol"},{"issue":"7","key":"991_CR56","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"A Jabbari","year":"2018","unstructured":"Jabbari A, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis. J Investig Dermatol. 2018;138(7):1539\u201345.","journal-title":"J Investig Dermatol"},{"issue":"3","key":"991_CR57","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jaad.2019.08.080","volume":"85","author":"CG Wambier","year":"2021","unstructured":"Wambier CG, Craiglow BG, King BA. Combination tofacitinib and oral minoxidil treatment for severe alopecia areata. J Am Acad Dermatol. 2021;85(3):743\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"991_CR58","doi-asserted-by":"publisher","first-page":"755","DOI":"10.5021\/ad.2017.29.6.755","volume":"29","author":"JW Choi","year":"2017","unstructured":"Choi JW, et al. Simvastatin\/ezetimibe therapy for recalcitrant alopecia areata: an open prospective study of 14 patients. Ann Dermatol. 2017;29(6):755\u201360.","journal-title":"Ann Dermatol"},{"issue":"1","key":"991_CR59","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jisp.2017.10.013","volume":"19","author":"J Cervantes","year":"2018","unstructured":"Cervantes J, et al. Treatment of alopecia areata with simvastatin\/ezetimibe. J Investig Dermatol Symp Proc. 2018;19(1):S25-s31.","journal-title":"J Investig Dermatol Symp Proc"},{"key":"991_CR60","unstructured":"U.S. Food and Drug Administration. IMURAN (azathioprine). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/016324s039lbl.pdf"},{"key":"991_CR61","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information - Cellcept (mycophenolate mofetil). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/050722s035,050723s035,050758s033,050759s041lbl.pdf"},{"key":"991_CR62","unstructured":"U.S. Food and Drug Administration. Azulfidine EN-tabs: sulfasalazine delayed release tablets, USP. Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from\nhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/007073s125lbl.pdf"},{"key":"991_CR63","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: XELJANZ\u00ae (tofacitinib). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/203214s018lbl.pdf"},{"key":"991_CR64","unstructured":"U.S. Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION: JAKAFI\u2122 (Ruxolitinib). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/202192lbl.pdf"},{"key":"991_CR65","unstructured":"U.S. Food and Drug Administration. Highlights of prescribing information: Olumiant (baricitinib). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/207924s000lbl.pdf"},{"key":"991_CR66","unstructured":"Pfizer. FDA and EMA Accept Regulatory Submission for Pfizer\u2019s Ritlecitinib for Individuals 12 Years and Older with Alopecia Areata. 2022 [cited 2023 20 February]; Available from: https:\/\/www.pfizer.com\/news\/pressrelease\/press-release-detail\/fda-and-ema-accept-regulatory-submission-pfizers"},{"key":"991_CR67","doi-asserted-by":"publisher","first-page":"363","DOI":"10.2147\/DDDT.S334727","volume":"16","author":"HA Ram\u00edrez-Mar\u00edn","year":"2022","unstructured":"Ram\u00edrez-Mar\u00edn HA, Tosti A (2022) Evaluating the therapeutic potential of Ritlecitinib for the treatment of Alopecia Areata. Drug Des Devel Ther 16:363\u2013374","journal-title":"Drug Des Devel Ther"},{"key":"991_CR68","unstructured":"U.S. Food and Drug Administration. VYTORIN \u00ae (ezetimibe\/simvastatin). Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021687s022lbl.pdf"},{"key":"991_CR69","unstructured":"U.S. Food and Drug Administration. Loniten\u00ae minoxidil tablets, USP. Drugs@FDA: FDA-Approved Drugs. Retrieved October 12, 2021, from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/018154s026lbl.pdf"},{"key":"991_CR70","unstructured":"National Institutes of Health. Prednisone tablets USP. U.S. National Library of Medicine. Retrieved October 12, 2021, from https:\/\/dailymed.nlm.nih.gov\/dailymed\/fda\/fdaDrugXsl.cfm?setid=efbe4ea2-e9b2-4e4c-a1b3-a323f61905c0&type=display"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-023-00991-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-023-00991-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T12:19:18Z","timestamp":1695903558000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-023-00991-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,9]]},"references-count":70,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["991"],"URL":"https:\/\/doi.org\/10.1007\/s13555-023-00991-3","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,9]]},"assertion":[{"value":"12 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}